19 March 2024 : Original article
Long-Term Outcomes with Prolonged-Release Tacrolimus in Kidney Transplantation: A Retrospective Real-World Data Analysis
Wilfried Gwinner1ABDE*, Swapneel Anaokar2ACDE, Martin Blogg2ACDE, Birgit Hermann3ACDE, Carola del Pilar Repetur2CDE, Mario Schiffer4ABDEDOI: 10.12659/AOT.942167
Ann Transplant 2024; 29:e942167
Table 2 Patient demographics per transplant center.
| Parameter | Center 1 (n=81) | Center 2 (n=82) | P value |
|---|---|---|---|
| Age, mean (SD) | 54.6 (12.3) | 46.6 (13.7) | <0.001 |
| Age ≥65 years, n (%) | 20 (24.7) | 8 (9.8) | 0.011 |
| Male, n (%) | 62 (76.5) | 55 (67.1) | 0.179 |
| Living donor, n (%) | 20 (24.7) | 35 (42.7) | 0.015 |
| ECD status, n (%) | 36 (44.4) | 9 (11.0) | <0.001 |
| Comorbidities at baseline (type 2 diabetes), n (%) | 18 (22.2) | 6 (7.3) | 0.007 |
| CMV donor IgG positive/recipient IgG negative, n (%) | 25 (30.9) | 19 (23.2) | 0.269 |
| CMV – cytomegalovirus; ECD – expanded criteria donor; IgG – immunoglobulin G; SD – standard deviation. Center 1, Universitäts-klinikum Erlangen; Center 2, Medizinische Hochschule Hannover. | |||